A Study to Evaluate Nasal Vestibulitis Symptoms in Patients Undergoing Systemic Antineoplastic Therapy

Overview

About this study

The purpose of this study is to evaluate treatment-emergent nasal vestibulitis symptoms in patients undergoing systemic antineoplastic therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age and be diagnosed with cancer.
  • Provide informed consent.
  • Ability to complete questionnaire(s) by themselves or with assistance.
  • Planned use of one of the defined systemic, antineoplastic therapies.
  • Willingness to complete questionnaires with each dose of therapy.
  • Plan to receive chemotherapy for the following 3-4 months OR a minimum of 4 cycles of chemotherapy given at intervals of 2 weeks or longer.
  • No prior chemotherapy over the previous 3 months.

Exclusion Criteria:

  1. Predisposition to frequent nosebleeds (more than once per month).
  2. Verbal baseline nasal dryness, pain, bleeding, or scabbing ≥ 2 on a 10 point scale (from mild=1 to severe=10).
  3. Planned receipt of two of the studied agents concurrently (e.g., abraxane and bevacizumab).
  4. Planned participation in a placebo-controlled trial.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Charles Loprinzi, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Mankato, Minn.

Mayo Clinic principal investigator

Stephan Thome, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Austin, Minn.

Mayo Clinic principal investigator

Mina Hanna, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Albert Lea, Minn.

Mayo Clinic principal investigator

Mina Hanna, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20409732

Mayo Clinic Footer